FDA Streamlines Approval Path for Neurizon's ALS Drug NUZ-001

The U.S. Food and Drug Administration has indicated that a single positive pivotal study could lead to traditional approval for Neurizon Therapeutics' ALS drug, NUZ-001. This accelerated pathway comes as the company completed enrollment for its Phase 2/3 HEALEY ALS Platform Trial ahead of schedule, with topline results anticipated in mid-2027. The FDA also invited Neurizon to reapply for Fast Track Designation, potentially expediting development.